|
|
|
|
Treatment of Depression in Adults Should Consider Children, Say Researchers
NRC/IOM Report Urges Physicians to Focus on Family Physicians and other health care professionals who treat adults with depression also should consider the effects of the illness on their patients' children, according to a new report from...
|
|
|
Death of man, 45, who had swine flu
A MAN with underlying medical conditions who died in a western Sydney hospital on Monday has tested positive to swine flu, NSW Health says.The coroner was investigating the degree to which influenza A(H1N1) 09 might have contributed to...
|
|
|
AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
The (AUA) Foundation has announced its Astellas Rising Stars in Urology for 2009.William Roberts, MD, of the University of Michigan, and Edward Schaeffer, MD, of Johns Hopkins Medicine are this year's recipients of the award, one of the...
|
|
|
Trial could lead to paradigm shift in RA treatment
A drug approved for advanced rheumatoid arthritis (RA) could save thousands of patients with early stage disease from disability, a new trial has shown.The research, presented at last weeks EULAR annual meeting in Copenhagen, Denmark,...
|
|
|
Copy Number Analysis Indicates Monoclonal Origin Of Lethal Metastatic Prostate Cancer
BERKELEY, CA (UroToday.com) - I was trained and board certified as a urologist (University of Virginia) and pathologist (Cornell and UVA) and arrived at Johns Hopkins in 1991 to do a research fellowship with Dr.William B. Isaacs,...
|
|
|
Bristol cyclists riding to raise cancer cash
A team of cyclists are preparing to ride 800 miles in eight days to raise funds for a Bristol cancer hospital.Oliver Isaacs is leading the Climb Against Cancer cycle through the most demanding stage of the Tour de France route to...
|
|
|
Bristol cyclists riding to raise cancer cash
A team of cyclists are preparing to ride 800 miles in eight days to raise funds for a Bristol cancer hospital.Oliver Isaacs is leading the Climb Against Cancer cycle through the most demanding stage of the Tour de France route to...
|
|
|
Drug Combination Helps Decelerate Progress of Arthritis
Researchers have found that patients dealing with the early stages of rheumatoid arthritis could benefit from a drug currently reserved for people in the advanced stages of the disease.Researchers studied 755 patients using rituximab,...
|
|
|
Drug slows early stage arthritis (source: BBC)
Accessibility Help A drug reserved for advanced rheumatoid arthritis (RA) could save thousands of people with early stage disease from disability, say researchers.Trials show rituximab, marketed as MabThera, almost completely halts the...
|
|
|
Drug slows early stage arthritis
The condition attacks the joints A drug reserved for advanced rheumatoid arthritis (RA) could save thousands of people with early stage disease from disability, say researchers.Trials show rituximab, marketed as MabThera, almost...
|
|
|
New one year X-Ray data in patients with early rheumatoid arthritis shows that rituximab (MabThera) plus metho
3935 live jobs on PharmiWeb.com now 15th June, Copenhagen: Rituximab (MabThera) in combination with methotrexate (MTX) given as the patient?s first biological therapy can significantly slow down joint damage compared to methotrexate alone...
|
|
|
MabThera improves outcomes in early RA, study shows
NEW data presented at the European League Against Rheumatism (EULAR) meeting in Copenhagen suggests a significant benefit from using Roche's MabThera earlier in the treatment path for rheumatoid arthritis.Results from the IMAGE study show...
|
|
|
EULAR: Good Efficacy Seen in RA for IL-6 Inhibitor
COPENHAGEN, June 15 -- An investigational biologic drug that blocks the interleukin-6 receptor was clinically and radiographically effective as second-line rheumatoid arthritis therapy, researchers said here.In a placebo-controlled phase...
|
|
|
EULAR: Good Efficacy Seen for IL-6 Inhibitor in RA
COPENHAGEN, June 15 -- An investigational biologic drug that blocks the interleukin-6 receptor was clinically and radiographically effective as second-line rheumatoid arthritis therapy, researchers said here.In a placebo-controlled phase...
|
|
|
Prognostic Markers for Rituximab Therapy in RA Patients Found
Rheumatoid arthritis patients who are sero-positive for either anti-CCP or rheumatoid factor (RF) antibodies are two to three times more likely to respond well to treatment with rituximab than those who dont have the autoantibodies,...
|
|
|
New drugs set to aid arthritis sufferers
A PATIENT developing rheumatoid arthritis (RA) today should be able to live a relatively normal existence because of new drug treatments, a leading expert in the field has said.Prof John Isaacs, professor of clinical rheumatology at...
|
|
|
New drugs set to aid arthritis sufferers
A PATIENT developing rheumatoid arthritis (RA) today should be able to live a relatively normal existence because of new drug treatments, a leading expert in the field has said.Prof John Isaacs, professor of clinical rheumatology at...
|
|
|
National Press Club Newsmaker Press Conference With Argonne Director Postponed
WASHINGTON, June 2 /PRNewswire-USNewswire/ -- The National Press Club Newsmaker press conference originally scheduled for 10 a.m.on Wednesday, June 3, with Argonne National Laboratory Director Eric Isaacs has been postponed. ...
|
|
|
National Press Club Newsmaker Press Conference With Argonne Director Postponed
WASHINGTON, June 2 /PRNewswire-USNewswire/ -- The National Press Club Newsmaker press conference originally scheduled for 10 a.m.on Wednesday, June 3, with Argonne National Laboratory Director Eric Isaacs has been postponed. ...
|
|
|
National Press Club Newsmaker Press Conference With Argonne Director Postponed
KSLA Health Connections Health WASHINGTON, June 2 /PRNewswire-USNewswire/ -- The National Press Club Newsmaker press conference originally scheduled for 10 a.m.on Wednesday, June 3, with Argonne National Laboratory Director Eric Isaacs...
|
|
|
Antibody engineering to develop new antirheumatic therapies
Arthritis Research & Therapy, 05/29/09 Print Save in My Library Free Full Text Isaacs JD Current review focuses on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments.
|
